Moreover, lumican decreased the expression levels of the mesenchymal markers slug/snail-2 zeb1, vimentin and fibronectin and the epithelial marker E-cadherin in MDA-MB-231 breast cancer cells. Here, SNAI2 is linked to breast cancer.